A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
for
Non-small Cell Lung Cancer
Location: New York NY, Lancaster PA, Greenville NC, Syracuse NY,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT06561386
Phase3, Recruiting
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
for
Non Small Cell Lung Cancer, Lung Cancer Metastatic,
Location: Chicago IL
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano